Home   Drug Development   CRO Services   Newsroom   About ReceptoPharm   Contact
» Recent News
» Archives
» E-Alerts
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More


Nutra Pharma Reports that ReceptoPharm will be Presenting at The Adrenomyeloneuropathy (AMN) Forum in London
February 08, 2005

Nutra Pharma Corp., a biotechnology holding company and incubator that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has today announced that its minority holding, ReceptoPharm, Inc., will make a presentation at the Adrenomyeloneuropathy Forum being held in London on Wednesday, February 9th.

The Adrenomyeloneuropathy Forum is a one-day event being held for physicians, researchers and patients interested in the current state of research for the treatment of AMN and its related symptoms. ReceptoPharm's Chief Executive Officer, Paul F. Reid, PhD, will be presenting to the Forum on the proposed Phase IIb/III study of RPI-78M in AMN.

"Nutra Pharma has agreed to support a Phase IIb/III trial in which the drug will be administered by injection over a fifteen-month trial period. Based on the data received in the previous trial, we believe that efficacy will be demonstrated," comments Rik Deitsch, Nutra Pharma's CEO. "This trial is expected to begin by the end of 2005," he added.

"We are excited at the opportunity to present ReceptoPharm's data and future trial protocol at The Adrenomyeloneuropathy Forum," stated Harold H. Rumph, ReceptoPharm's President. "This is an important step in moving RPI-78M through the clinical process and eventually through regulatory approval," he concluded.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Presenting at the Adrenomyeloneuropathy Forum in London should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Recent News
November 05, 2010
Nutra Pharma Awarded Grant under the Qualifying Therapeutic Discovery Project Program
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name: